UFASOMES: UNSATURATED FATTY ACID BASED VESICULAR DRUG DELIVERY SYSTEM
Various novel drug delivery systems have been developed encompassing several administration routes to deliver drugs at a rate decided as per the need of the body during the course of treatment and to achieve targeted therapy, also decreases undesirable side effects. Different types of vesicular drug delivery systems were developed, such as liposomes, niosomes, ufasomes etc. Ufasomes are unsaturated fatty acid vesicles which is a suspension of closed lipid bilayer formed from fatty acid and their ionized species having limited, narrow pH ranging from 7-9. Composition of fatty acid molecules is such that the hydrocarbon tails are pointed towards the inner core of the membrane and the carboxyl group are in touch with water. Stable ufasomes preparation mainly relies on appropriate choice of fatty acid, cholesterol quantity, range of the pH, buffer and lipoxygenase amount. Recent innovation provides very efficient features such as stability considerations, dynamic features and microscopic features of ufasomes. The article furthermore provides the difference between ufasomes with liposomes. For this review, the complete databases have been collected from various search engines such as researchgate, elsevier, pubmed, sciencedirect, google scholar, scopus etc., from the year 1965-2020 using the following keywords.
2. Kamboj S, Saini V, Magon N, Suman Bala, Jhawat V. Vesicular drug delivery systems: a novel approach for drug targeting. Int J Drug Delivery 2013;5:121-30.
3. Mujoriya R, Bodla RB, Dhamande K, Singh D, Patle L. Niosomal drug delivery system: the magic bullet. J Appl Pharm Sci 2011;9:20-3.
4. Bangham AD, Standish MM, Watkins JG. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965;13:238-52.
5. Goldberg EP. Eds. In: Targeted Drugs. 2nd edition. Wiley, New York; 1983. p. 312.
6. Poste G, Krisch R, Koestler T. Liposome technology. CRC Press Inc, Banco Raton, F1; 1983;3:29.
7. Nair AJ, Raju J, Arya GK, Nair SC. Bicosome: a versatile technology in biomedicine and dermopharmacy. Int J Res Pharm Sci 2018;10:186-95.
8. Pandita A, Sharma P. Pharmacosomes: an emerging novel vesicular drug delivery system for poorly soluble synthetic and herbal drugs. ISRN Pharm 2013. p. 1-0.
9. Biju SS, Talegaonkar S, Mishra PR, Khar RK. Vesicular system an overview. Indian J Pharm Sci 2006;68:141-53.
10. Buchiraju R, Nama S, Sakala B, Chandu RB, Kommu A, Chebrolu JKB, et al. Vesicular drug delivery system-an overview. Res J Pharm Biol Chem Sci 2013;4:462-74.
11. Kharat A, Pawar P. Novel drug delivery system in herbal’s. Int J Pharm Chem Biol Sci 2014;4:910-30.
12. Kumar D, Sharma D, Singh G, Singh M, Rathore MS. Lipoidal soft hybrid biocarriers of supramolecular construction for drug delivery. ISRN Pharm 2012;1-14. DOI:10.5402/2012/474830
13. Jain S, Jain V, Mahajan SC. Lipid-based vesicular drug delivery systems. Adv Pharm 2014;1-12. https://doi.org/10.1155/ 2014/574673
14. Sarangi MK, Padhi S. Colon targeted drug delivery system-an approach for treating colonic ailments. J Crit Rev 2015;2:12-8.
15. Vaidya AV, Shinde UA, Shimpi HH. Preliminary studies on brain targeting of intranasal atomoxetine liposomes. Int J Pharm Pharm Sci 2016;8:286-92.
16. Gill V, Nanda A. Preparation and characterization of etodolac bearing emulsomes. Int J Appl Pharm 2020;12:166-72.
17. Abdelgawad R, Nasr M, Hamza MY, Awad GAS. Topical and systemic dermal carriers for psoriasis. Int J Curr Pharm Res 2016;8:4-9.
18. Rajan R, Jose S, Mukund VPB, Vasudevan DT. Transferosomes-a vesicular transdermal delivery system for enhanced drug permeation, J Adv Pharm Technol Res 2011;2:138-43.
19. S Lankalapalli, M Damuluri. Sphingosomes: application in targeted drug delivery. Res J Pharm Biol Chem Sci 2012;2:507-16.
20. Zishan M, Kushwaha P, Singh K, Amir M, Ansari VA, Sirbaiya AK, et al. An overview of: vesicular drug delivery system. World J Pharm Pharm Sci 2017;6:546-60.
21. Semalty A, Semalty M, Singh D, Rawat MSM. Development and physicochemical evaluation of pharmacosomes of diclofenac. Acta Pharm 2009;59:335-44.
22. Shefrin S, Sreelaxmi CS, Vijayan V, Nair SC. Enzymosomes: a rising effectual tool for targeted drug delivery system. Int J Appl Pharm 2017;9:1-9.
23. Sutariya V, Patel P. Aquasomes: a novel carrier for drug delivery. Int J Pharm Sci Res 2012;3:688-94.
24. Nair SC, Kumar BS, Krishna R, PS Lakshmi, Vasudev DT. Formulation and evaluation of niosomal suspension of cefixime. Asian J Pharm Clin Res 2017;10:194-201.
25. Khan R, Irchhaiya R. In vitro in vivo evaluation of niosomal formulation of famotidine. Int J Pharm Pharm Sci 2020;12:15-22.
26. Arora D, Khurana B, Kumar MS, Vyas SP. Oral immunization against hepatitis B virus using mannosylated bilosomes. Int J Recent Adv Pharm Res 2011;1:45-51.
27. Morigaki K, Walde P. Fatty acid vesicles. Curr Opin Colloid Interface Sci 2007;12:75-80.
28. Gebicki JM, Hicks M. Ufasomes are stable particles surrounded by unsaturated fatty acid membranes. Nature 1973;243:232-4.
29. Hicks M, Gebicki JM. Preparation and properties of vesicles enclosed by fatty acid membranes. Chem Phys Lipids 1976;16:142-60.
30. Hargreaves WR, Deamer DW. Liposomes from ionic, single-chain amphiphiles. Biochemistry 1978;17:3759-68.
31. Fan Y, Fang Y, Ma L. The self-crosslinked ufasome of conjugated linoleic acid: Investigation of morphology, bilayer membrane and stability. Colloids Surf B 2014;123:8-14.
32. Nair AJ, K Aswathi, George A, PP Athira, Nair SC. Ufasome: a potential phospholipid carrier as a novel pharmaceutical formulation. Int Res J Pharm 2014;5:250-3.
33. Namani T, Walde P. From decanoate micelles to decanoic acid/dodecyl benzenesulfonate vesicles. Langmuir 2005;21:6210-9.
34. Patel DM, Jani RH, Patel CN. Ufasomes: a vesicular drug delivery. Syst Rev Pharm 2011;2:72-8.
35. Caschera F, Stano P, Luisi PL. Reactivity and fusion between cationic vesicles and fatty acid anionic vesicles. J Colloid Interface Sci 2010;345:561-75.
36. Fukuda H, Goto A, Yoshioka H, Goto R, Morigaki K, Walde P. Electron spin resonance study of the pH-induced transformation of micelles to vesicles in an aqueous oleic acid/oleate system. Langmuir 2001;17:4223-31.
37. Hicks M, Gebicki JM. Inhibition of peroxidation in linoleic acid membranes by nitroxide radicals, butylated hydroxytoluene, and ?-tocopherol. Arch Biochem Biophys 1981;210:56-63.
38. McLean LR, Hagaman KA. Effect of lipid physical state on the rate of peroxidation of liposomes. Free Radical Biol Med 1992;12:113-9.
39. Aruoma OI, Halliwell B, Laughton MJ, Quinlan GL, Gutteridge JM. The mechanism of initiation of lipid peroxidation: Evidence against a requirement for an iron (II)-iron (III) complex. Biochem J 1989;258:617-20.
40. Scarpa M, Rigo A, Maiorino M, Ursini F, Gregolin C. Formation of ?-tocopherol radical and recycling of ?-tocopherol by ascorbate during peroxidation of phosphatidylcholine liposomes: an electron paramagnetic resonance study. Biochim Biophys Acta 1984;28:215-9.
41. Gutteridge JM, Quinlan GJ, Clark I, Halliwell B. Aluminium salts accelerate peroxidation of membrane lipids stimulated by iron salts. Biochim Biophys Acta 1985;835:441-7.
42. Barenholz Y. Liposome application: problems and prospects. Curr Opin Colloid Interface Sci 2001;6:66-77.
43. Namani T, Ishikawa T, Morigaki K, Walde P. Vesicles from docosahexaenoic acid. Colloids Surf B 2007;54:118-23.
44. Borne J, Nylander T, Khan A. Vesicle formation and other structures in aqueous dispersions of monoolein and sodium oleate. J Colloid Interface Sci 2003;257:310-20.
45. Roy S, Dey J. Self-organization and microstructures of sodium 11-acrylamidoundecanoate in water. Langmuir 2003;19:9625-9.
46. Nayak RR, Roy S, Dey J. Characterization of polymeric vesicles of poly (sodium 11-acrylamidoundecanoate) in water. Colloid Polym Sci 2006;285:219-24.
47. Hao J, Liu W, Xu G, Zheng L. Vesicles from salt-free cationic and anionic surfactant solutions. Langmuir 2003;19:10635-40.
48. Chen IA, Szostak JW. A kinetic study of the growth of fatty acid vesicles. Biophys J 2004;87:988-98.
49. Hicks M, Gebicki JM. Microscopic studies of fatty acid vesicles. Chem Phys Lipids 1976;20:243-52.
50. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv 1995;70:95-111.
51. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: Dermal and transdermal drug delivery. J Controlled Release 1994;30:1-15.
52. Vandenbergh BA, Salomonsdevries I, Bouwstra JA. Interactions between liposomes and human stratum corneum studied by freeze-substitution electron microscopy. Int J Pharm 1998;167:57-67.
53. Robenek H, Severs NJ. Recent advances in freeze-fracture electron microscopy: the replica immunolabeling technique. Biol Proced Online 2008;10:9-19.
54. Guiot P, Baudhuin P, Gotfredsen C. Morphological characterization of liposome suspensions by stereological analysis of freeze-fracture replicas from spray-frozen samples. J Microsc 1980;120:159-74.
55. Mishima K, Satoh K, Ogihara T. Optical birefringence of phosphatidylcholine liposomes in gel phases. Biochim Biophys Acta 1987;898:231-8.
56. Bolla PK, Meraz CA, Rodriguez VA, Deaguero I, Singh M, Yellepeddi VK, et al. Clotrimazole loaded ufosomes for topical delivery: formulation development and in vitro studies. Molecules 2019;24:31-9.
57. Verma S, Bhardwaj A, Vij M, Bajpai P, Goutam N, Kumar L. Oleic acid vesicles: a new approach for topical delivery of antifungal agent. Artif Cells Nanomed Biotechnol 2014;42:95-101.
58. Zakir F, Vaidya B, Goyal AK, Malik B, Vyas SP. Development and characterization of oleic acid vesicles for the topical delivery of fluconazole. Drug Delivery 2010;17:238-48.
59. Kumar P, Singh S, Handa V, Kathuria H. Oleic acid nanovesicles of minoxidil for enhanced follicular delivery. Medicines 2018;5:103.
60. Salama AH, Aburahma MH. Ufasomes nano-vesicles-based lyophilized platforms for intranasal delivery of cinnarizine: preparation, optimization,ex-vivohistopathological safety assessment and mucosal confocal imaging. Pharm Dev Technol 2016;21:706-15.
61. Sharma A, Arora S. Dermal delivery of glucosamine sulphate: formulation, characterization and performance evaluation. World J Pharm Pharm Sci 2013;2:6448-62.
62. Vanhoogdalem EJ, Deboer AG, Bireimer DD. Intestinal drug absorption enhancement: an overview. Pharmacol Ther 1989;44:407-43.
63. Fukui H, Murakami M, Takada K, Muranishi S. Combinative promotion effect of Azone and fusogenic fatty acid on the large intestinal absorption in rat. Int J Pharm 1986;31:239-46.
64. Patel HM, Ryman BE. Oral administration of insulin by encapsulation within liposomes. FEBS Lett 1976;62:60-3.
65. Patel HM, Stevenson RW, Parsons JA, Ryman BE. Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs. Biochem Biophys Acta 1982;716:188-93.
66. Takeuchi H, Yamamoto H, Hino T, Kawashima Y. Enteral absorption of insulin in rats from mucoadhesive chitosan coated liposomes. Pharm Res 1996;13:896-901.
This work is licensed under a Creative Commons Attribution 4.0 International License.